Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5.3 billion in its U.S. initial public offering, as the market for new listings rebounds. Irving, Texas-based Caris, backed by investment firm Sixth Street, is seeking up to $423.5 million by offering 23.5 million shares priced between $16 and $18 apiece. The IPO market is heating up as high-profile companies move ahead with their stock market listings in a calmer period after tariff-related volatility stifled deal activity earlier this year.
Read the full article: Sixth Street-Backed Caris Life Sciences Targets $5.3B Valuation in US IPO //
Source: https://finance.yahoo.com/news/sixth-street-backed-caris-life-112745993.html